TY - JOUR
T1 - Pre-diagnostic plasma advanced glycation end-products and soluble receptor for advanced glycation end-products and mortality in colorectal cancer patients
AU - Li, Jinze
AU - Roshelli Baker, Jacqueline
AU - Aglago, Elom K
AU - Zhao, Zhiwei
AU - Jiao, Li
AU - Freisling, Heinz
AU - Hughes, David J
AU - Eriksen, Anne Kirstine
AU - Tjønneland, Anne
AU - Severi, Gianluca
AU - Katzke, Verena
AU - Kaaks, Rudolf
AU - Schulze, Matthias B
AU - Masala, Giovanna
AU - Pala, Valeria
AU - Pasanisi, Fabrizio
AU - Tumino, Rosario
AU - Padroni, Lisa
AU - Vermeulen, Roel C H
AU - Gram, Inger T
AU - Braaten, Tonje
AU - Jakszyn, Paula Gabriela
AU - Sánchez, Maria-José
AU - Gómez-Gómez, Jesús-Humberto
AU - Moreno-Iribas, Conchi
AU - Amiano, Pilar
AU - Papier, Keren
AU - Weiderpass, Elisabete
AU - Huybrechts, Inge
AU - Heath, Alicia K
AU - Schalkwijk, Casper
AU - Jenab, Mazda
AU - Fedirko, Veronika
N1 - Publisher Copyright:
© 2024 UICC.
PY - 2024/7/26
Y1 - 2024/7/26
N2 - Advanced glycation end-products (AGEs), formed endogenously or obtained exogenously from diet, may contribute to chronic inflammation, intracellular signaling alterations, and pathogenesis of several chronic diseases including colorectal cancer (CRC). However, the role of AGEs in CRC survival is less known. The associations of pre-diagnostic circulating AGEs and their soluble receptor (sRAGE) with CRC-specific and overall mortality were estimated using multivariable-adjusted Cox proportional hazards regression among 1369 CRC cases in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Concentrations of major plasma AGEs, N
ε-[carboxy-methyl]lysine (CML), N
ε-[carboxy-ethyl]lysine (CEL) and N
δ-[5-hydro-5-methyl-4-imidazolon-2-yl]-ornithine (MG-H1), were measured using ultra-performance liquid chromatography mass-spectrometry. sRAGE was assessed by enzyme-linked immunosorbent assay. Over a mean follow-up period of 96 months, 693 deaths occurred of which 541 were due to CRC. Individual and combined AGEs were not statistically significantly associated with CRC-specific or overall mortality. However, there was a possible interaction by sex for CEL (P
interaction = .05). Participants with higher sRAGE had a higher risk of dying from CRC (HR
Q5vs.Q1 = 1.67, 95% CI: 1.21-2.30, P
trend = .02) or any cause (HR
Q5vs.Q1 = 1.38, 95% CI: 1.05-1.83, P
trend = .09). These associations tended to be stronger among cases with diabetes (P
interaction = .03) and pre-diabetes (P
interaction <.01) before CRC diagnosis. Pre-diagnostic AGEs were not associated with CRC-specific and overall mortality in individuals with CRC. However, a positive association was observed for sRAGE. Our findings may stimulate further research on the role of AGEs and sRAGE in survival among cancer patients with special emphasis on potential effect modifications by sex and diabetes.
AB - Advanced glycation end-products (AGEs), formed endogenously or obtained exogenously from diet, may contribute to chronic inflammation, intracellular signaling alterations, and pathogenesis of several chronic diseases including colorectal cancer (CRC). However, the role of AGEs in CRC survival is less known. The associations of pre-diagnostic circulating AGEs and their soluble receptor (sRAGE) with CRC-specific and overall mortality were estimated using multivariable-adjusted Cox proportional hazards regression among 1369 CRC cases in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Concentrations of major plasma AGEs, N
ε-[carboxy-methyl]lysine (CML), N
ε-[carboxy-ethyl]lysine (CEL) and N
δ-[5-hydro-5-methyl-4-imidazolon-2-yl]-ornithine (MG-H1), were measured using ultra-performance liquid chromatography mass-spectrometry. sRAGE was assessed by enzyme-linked immunosorbent assay. Over a mean follow-up period of 96 months, 693 deaths occurred of which 541 were due to CRC. Individual and combined AGEs were not statistically significantly associated with CRC-specific or overall mortality. However, there was a possible interaction by sex for CEL (P
interaction = .05). Participants with higher sRAGE had a higher risk of dying from CRC (HR
Q5vs.Q1 = 1.67, 95% CI: 1.21-2.30, P
trend = .02) or any cause (HR
Q5vs.Q1 = 1.38, 95% CI: 1.05-1.83, P
trend = .09). These associations tended to be stronger among cases with diabetes (P
interaction = .03) and pre-diabetes (P
interaction <.01) before CRC diagnosis. Pre-diagnostic AGEs were not associated with CRC-specific and overall mortality in individuals with CRC. However, a positive association was observed for sRAGE. Our findings may stimulate further research on the role of AGEs and sRAGE in survival among cancer patients with special emphasis on potential effect modifications by sex and diabetes.
KW - advanced glycation end-products (AGEs)
KW - colorectal cancer
KW - mortality
KW - soluble receptor of AGEs (sRAGE)
UR - http://www.scopus.com/inward/record.url?scp=85199872008&partnerID=8YFLogxK
U2 - 10.1002/ijc.35114
DO - 10.1002/ijc.35114
M3 - Article
C2 - 39057841
SN - 0020-7136
VL - 155
SP - 1982
EP - 1995
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 11
ER -